|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15 Pt 1
|
|
pubmed:dateCreated |
2007-8-2
|
|
pubmed:abstractText |
The immunomodulatory properties of Toll-like receptors (TLR) agonists have inspired their use as experimental adjuvants for vaccination of cancer patients. However, it is now well recognized that TLR expression is not restricted to immune cells but can also be found in many cell types, including those giving rise to tumors. It is therefore mandatory to explore the potential effects of TLR triggering directly on tumor cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4565-74
|
|
pubmed:meshHeading |
pubmed-meshheading:17671143-Apoptosis,
pubmed-meshheading:17671143-Caspases,
pubmed-meshheading:17671143-Cell Proliferation,
pubmed-meshheading:17671143-Humans,
pubmed-meshheading:17671143-Immunoprecipitation,
pubmed-meshheading:17671143-Interferon-alpha,
pubmed-meshheading:17671143-Lentivirus,
pubmed-meshheading:17671143-Melanoma,
pubmed-meshheading:17671143-Poly I-C,
pubmed-meshheading:17671143-RNA Interference,
pubmed-meshheading:17671143-Skin Neoplasms,
pubmed-meshheading:17671143-Toll-Like Receptor 3
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Toll-like receptor 3 expressed by melanoma cells as a target for therapy?
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
